Kura Oncology Inc KURA

Healthcare Biotechnology

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia patients with high unmet need. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is a next-generation FTI, which demonstrates improved potency, pharmacokinetic and physicochemical properties relative to earlier FTI drug candidates.

NDAQ:KURA - Post by User

Kura Oncology Inc

<< Previous

Bullboard Posts

Post by whytestockson Apr 22, 2024 1:15pm

30 Views

Post# 36001598

Kura Oncology Receives Breakthrough Therapy Designation for

Just In: $KURA Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML– Ziftomenib is the first investigational treatment to be granted Breakthrough Therapy Designation for NPM1-mutant AML – – Registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete enrollment by mid-2024 – SAN DIEGO, April 22, 2024 (GLOB...KURA - Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML

<< Previous

Bullboard Posts

Nine Mile Metals completes acquisition of 3 properties